chufangao/CTO huggingface dataset:
Clinical trial NCT01942135: Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Official title: MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 521.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-09-26
Primary completion date: 2014-12-05
Completion date: 2022-09-28
Baseline population: The intent-to-treat (ITT) population or full analysis set included all participants who were randomized, with study intervention assignment designated according to initial randomization, regardless of whether participants received study intervention or received a different drug from that to which they were randomized.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03811574: STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
Official title: Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity
Acronym: STEP 6
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 401.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-01-21
Primary completion date: 2020-11-20
Completion date: 2020-11-20
Baseline population: Full analysis set (FAS) included all randomised participants.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT04806529: An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
Official title: A Phase 2/3 Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Immunogenicity and Safety of the Adjuvanted SARS-CoV-2 Subunit Vaccine in Adults Aged 18 Years and Above
Sponsor: Seqirus (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Seqirus discontinued V451_07 Phase 2 start-up activities prior to enrolling subjects. Data from Phase 1 did not support further development. Further details are here: www.seqirus.com/news/update-on-the-university-of-queensland-covid-19-vaccine
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-15
Primary completion date: 2020-12-15
Completion date: 2022-04-09
Plan to share individual participant data: YES
IPD sharing description: SEQIRUS supports the release of anonymized subject-level and study-level data in compliance with regulatory requirements, including Clinical Documents which are part of the CTD modules submitted to regulatory agencies for public release.~Summary results disclosure is either in document form (e.g., ICH E3 Clinical Study Report synopsis) or structured data form (such as summary results in ClinicalTrials.gov (United States) or eudract.ema.europa.eu (EU Clinical Trial Registry \[EU CTR\])~Supporting Information:~* Study Protocol~* Statistical Analysis Plan (SAP)
IPD time frame: SEQIRUS discloses results from clinical studies within 12 months of last patient last visit (LPLV) unless otherwise mandated by local laws or regulations.
IPD access criteria: Access: SEQIRUS considers requests from qualified scientific and medical researchers to disclose protocols, anonymized subject-level data and study-level data when there is medical, scientific and/or public health interest to ensure the safe use of a Seqirus product licensed on or after 1 January 2014 in the US and/or EU. This applies to Seqirus-sponsored interventional studies initiated after 27 September 2007 and ongoing as of 26 December 2007, that have been included as part of a US or EU submission package which received approval in US and EU on or after 1 January 2014 and have been accepted for publication
Clinical trial NCT04720547: Sleep and Breathing in the General Population - Chemical Stimuli
Official title: Sleep and Breathing in Health and Disease (Part 2A - Chemical Stimuli, Sleep and Breathing in the General Population)
Sponsor: Wayne State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-03
Primary completion date: 2020-02-29
Completion date: 2020-02-29
Plan to share individual participant data: NO
Clinical trial NCT06018116: A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
Official title: A Canadian Phase II, Placebo-controlled Randomized Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.
Acronym: CANUCK-01
Sponsor: CHU de Quebec-Universite Laval (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Results of EV302 study do not make it feasible to complete a study in second line avelumab immunotherapy. The new standard of care make this study not pertinent.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-11-07
Primary completion date: 2024-01-31
Completion date: 2024-02-12
Plan to share individual participant data: NO
Clinical trial NCT02525796: Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Official title: Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 69.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-01-31
Primary completion date: 2021-10-01
Completion date: 2021-10-02
Baseline population: Patient with primary hyperparathyroidism
Plan to share individual participant data: YES
IPD sharing description: IPD will be shared with interested investigators upon request 1 year after the study is completed. Investigators may request IPD by contacting the PI and proposing a data analysis plan
Clinical trial NCT02832531: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
Official title: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies
Acronym: INVICTUS-ASA
Sponsor: Population Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Focus on recruitment for non-inferiority trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2022-04-30
Completion date: 2022-08-31
Plan to share individual participant data: NO
IPD sharing description: cumulative participant data only
Clinical trial NCT05248867: A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Official title: A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 638.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-16
Primary completion date: 2023-03-17
Completion date: 2023-03-17
Baseline population: Intent to Treat Population: all randomized participants, analyzed according to the treatment groups to which they were randomized
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT04396340: First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Official title: A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1592 In Patients With Solid Tumors Likely to Express NaPi2b
Sponsor: Mersana Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: discontinued development program
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-11
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT03939364: This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions
Official title: A Phase 1, Randomized, Double-blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of SBS-101 After Intraoral Application in Patients With Oral Premalignant Lesions (OPL)
Sponsor: Skyline Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Delays due to manufacturing and the COVID-19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-01-31
Primary completion date: 2023-04-30
Completion date: 2023-05-31
Clinical trial NCT04545385: A Study to Test if TEV-48574 is Effective in Relieving Asthma
Official title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Met pre-specified criteria for futility at interim analysis
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-07
Primary completion date: 2022-01-17
Completion date: 2022-01-17
Baseline population: The intent-to-treat (ITT) analysis set included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)
Clinical trial NCT04169698: Alendronate Versus Denosumab in Kidney Transplant Patients
Official title: Evaluation of the Efficacy and Tolerability of Alendronate Versus Denosumab in Kidney Transplant Patients With Reduced Bone Mineral Density
Sponsor: Ain Shams University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 90.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-10-17
Primary completion date: 2021-05-01
Completion date: 2021-05-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03605589: Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Official title: A Pilot Study of Blinatumomab in Combination With a PD1 Inhibitor, Pembrolizumab, in Pediatric and Young Adult Patients With Relapsed/Refractory CD19 Positive B-cell Acute Leukemia or Lymphoma
Sponsor: Children's Hospital Medical Center, Cincinnati (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Lack of enrollment due to the availability of other novel salvage therapies for relapsed/refractory B-ALL.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-27
Primary completion date: 2021-08-31
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT03137537: Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Official title: Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funding terminated
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-27
Primary completion date: 2020-11-18
Completion date: 2020-11-18
Plan to share individual participant data: NO
Clinical trial NCT04272645: Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
Official title: A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Coordinating site change
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-10-31
Primary completion date: 2022-10-31
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT05603143: Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression
Acronym: BIRCH
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was stopped early as it was determined there would not be a statistically significant treatment effect associated with the primary endpoint due to the low number of events.
Enrollment: 468.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-05
Primary completion date: 2023-11-07
Completion date: 2023-11-07
Plan to share individual participant data: NO
Clinical trial NCT03582085: Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia
Official title: Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No funding at the current time.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-01
Primary completion date: 2023-01-01
Completion date: 2023-01-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05051449: Ketamine for OUD and Comorbid Depression (OUDCD)
Official title: Increasing Retention in Methadone Maintenance Treatment: Feasibility and Preliminary Efficacy of Ketamine for the Treatment of Patients With OUD and Comorbid Depression (OUDCD)
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study funds were exhausted
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-04
Primary completion date: 2023-11-17
Completion date: 2023-11-30
Plan to share individual participant data: NO
Clinical trial NCT04236453: A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents
Official title: A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Subjects to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 mg When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents (Darunavir, Cobicistat, and Emtricitabine/Tenofovir Alafenamide), Under Fed Conditions
Sponsor: Janssen Pharmaceutica N.V., Belgium (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: COVID-19 pandemic impacted the BE assessment of the trial. The clinical team decided to terminate the trial in order to start a new pivotal BE trial
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-23
Primary completion date: 2020-04-10
Completion date: 2020-04-10
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT02846831: Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes
Official title: An Open-label, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy and Sensor-augmented Pump Therapy in Regulating Glucose Levels for 12 Days in Free-living Outpatient Conditions in Patients With Type 1 Diabetes
Sponsor: Institut de Recherches Cliniques de Montreal (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-24
Primary completion date: 2020-01-27
Completion date: 2020-01-27
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03837860: Reducing the Abuse of Opioids in Drug Users
Official title: Reducing the Abuse Liability of Prescription Opioids in Recreational Drug Users: A Pilot Study
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: PI leaving institution
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-04-01
Primary completion date: 2021-03-23
Completion date: 2022-01-21
Plan to share individual participant data: NO
Clinical trial NCT03312855: Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
Official title: Revacept, a Novel Inhibitor of Platelet Adhesion in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: a Phase II, Multicentre, Randomised, Double-blind and Placebo-controlled Study
Acronym: ISAR-PLASTER
Sponsor: Deutsches Herzzentrum Muenchen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 334.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-11-20
Primary completion date: 2020-02-29
Completion date: 2020-03-26
Plan to share individual participant data: NO
Clinical trial NCT03068780: Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Official title: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow-up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Acronym: EASE
Sponsor: Amryt Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 223.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-29
Primary completion date: 2020-06-11
Completion date: 2022-05-27
Plan to share individual participant data: NO
Clinical trial NCT03002506: Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
Official title: Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
Sponsor: Texas Tech University Health Sciences Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Much slower recruitment than anticipated
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-21
Primary completion date: 2020-06-01
Completion date: 2020-06-30
Baseline population: All participants who provided informed consent and received ceftolozane/tazobactam.
Limitations and caveats: Single-dose pharmacokinetic study. No clinical outcomes to evaluate efficacy. No safety data provided by this study beyond a single dose in this population.
Plan to share individual participant data: NO
Clinical trial NCT03979664: Iontophoresis in Psoriasis
Official title: Efficacy of Dexamethasone Iontophoresis in Psoriasis
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: FDA did not provide approval of the use of the drug for the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-31
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02911714: Contrast-Enhanced Ultrasound for Kidney Transplant
Official title: A Pilot Study to Develop Contrast-Enhanced Ultrasound for Kidney Transplant
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: lack of funding
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-21
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT02838030: Efficacy of Aspirin and L-arginine in High Risk Preeclamptic
Official title: Efficacy of the Combination of Acetylsalicylic Acid and L-arginine to Prevent Preeclampsia in Pregnant High Risk
Sponsor: University of Guadalajara (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: COVID-19 pandemic
Enrollment: 82.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2018-07-01
Primary completion date: 2021-07-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT03916068: Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy
Official title: A Pilot Study Comparing Acute Post-Radiation Hyperbaric Oxygen (HBO2) Versus Trental and Vitamin E for Breast Cancer Patients Who Have Recently Completed Radiation Therapy as Part of Their Treatment Course
Sponsor: Legacy Health System (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient enrollment
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-01
Primary completion date: 2023-10-02
Completion date: 2023-10-02
Plan to share individual participant data: NO
Clinical trial NCT04341610: ASC Therapy for Patients With Severe Respiratory COVID-19
Official title: Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study
Acronym: ASC COVID-19
Sponsor: Rigshospitalet, Denmark (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Not approved by ethical committee
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-20
Primary completion date: 2021-01-30
Completion date: 2021-04-30
Plan to share individual participant data: UNDECIDED